COMPANY

Osel

HQ: Mountain View, CA source · oselinc.com ↗ · West Coast

Keywords: microbiome women's health Bacterial Vaginosis Advanced Clear Cell Renal Cell Carcinoma Advanced Renal Cell Carcinoma Advanced Sarcomatoid Renal Cell Carcinoma Metastatic Clear Cell Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Metastatic Sarcomatoid Renal Cell Carcinoma Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Clostridium Difficile Infection cervical cancer CBM588 LACTIN-V

Location: Mountain View, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)48NIH grants

Timeline

Jun 19, 2024 Trial start Phase 1: CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer source ↗
2010-02 Trial start Phase 2: Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections source ↗
2008-04 Trial start Phase 2: Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis source ↗
2007-11 Trial start Phase 1: Safety Study of Lactobacillus Administered Vaginally to Healthy Women source ↗

Upcoming milestones

Oct 19, 2026 (ESTIMATED) · Phase 1 · CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer · NCT06399419

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06399419	CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer	Phase 1	Recruiting	Jun 19, 2024	Oct 19, 2026 (estimated)
NCT00537576	Safety Study of Lactobacillus Administered Vaginally to Healthy Women	Phase 1	Completed	2007-11	2008-03 (actual)
NCT01077245	Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections	Phase 2	Withdrawn	2010-02	2013-11 (actual)
NCT00635622	Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis	Phase 2	Completed	2008-04	2009-01 (actual)

NIH awards 48

Annual award amounts. Total $22.3M.

May 20, 2025 NIH award 1R43CA297979-01 FY2025: $295,881 awarded for that fiscal year; activity R43 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Novel Antimicrobial Approach to Treat Chemora source ↗
Aug 3, 2021 NIH award 5R44AI149807-02 FY2021: $463,683 awarded for that fiscal year; activity R44 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. MucoCept-CVN, a genetically enhanced vaginal source ↗
Jul 27, 2020 NIH award 1R44AI149807-01 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. MucoCept-CVN, a genetically enhanced vagina source ↗
Mar 22, 2016 NIH award 1R43AI124960-01 FY2016: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a rapid point of care diagnost source ↗
Jul 15, 2015 NIH award 5R44AI100753-03 FY2015: $1,388,546 awarded for that fiscal year; activity R44 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Delivery of passive immunity against HIV us source ↗
Aug 6, 2014 NIH award 2R44AI100753-02 FY2014: $1,335,502 awarded for that fiscal year; activity R44 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Delivery of passive immunity against HIV us source ↗
Mar 20, 2012 NIH award 1R43AI100753-01 FY2012: $299,870 awarded for that fiscal year; activity R43 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Delivery of passive immunity against HIV usin source ↗
Aug 17, 2011 NIH award 5R33AI071978-05 FY2011: $364,466 awarded for that fiscal year; activity R33 (OTHER_NIH); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a Live Topical Microbicid source ↗
Sep 29, 2010 NIH award 3R33AI071978-04S1 FY2010: $425,654 awarded for that fiscal year; activity R33 (OTHER_NIH); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a Live Topical Microbic source ↗
Aug 9, 2010 NIH award 5R33AI071978-04 FY2010: $345,570 awarded for that fiscal year; activity R33 (OTHER_NIH); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a Live Topical Microbicid source ↗
Jul 26, 2010 NIH award 1R43AI089146-01 FY2010: $198,503 awarded for that fiscal year; activity R43 (SBIR); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of Bacterial Therapeutics Targeti source ↗
Mar 5, 2010 NIH award 5R21AI079799-02 FY2010: $195,122 awarded for that fiscal year; activity R21 (OTHER_NIH); PI LAGENAUR, LAUREL A.; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a Live Combinational Micr source ↗
Sep 24, 2009 NIH award 4R33AI071978-03 FY2009: $339,396 awarded for that fiscal year; activity R33 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a Live Topical Microbicide for Wome source ↗
Mar 13, 2009 NIH award 1R21AI079799-01A1 FY2009: $187,422 awarded for that fiscal year; activity R21 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a Live Combinational Microbicide source ↗
Aug 25, 2008 NIH award 5U01AI066708-04 FY2008: $556,415 awarded for that fiscal year; activity U01 (OTHER_NIH); PI PARKS, THOMAS P; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. MucoCept: a Live Topical Microbicide for Wom source ↗
Aug 18, 2008 NIH award 5R21AI071978-02 FY2008: $203,512 awarded for that fiscal year; activity R21 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., MOUNTAIN VIEW, CA. Development of a Live Topical Microbicide for Wome source ↗
Sep 24, 2007 NIH award 1R21AI071978-01A1 FY2007: $198,290 awarded for that fiscal year; activity R21 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., Mountain View, CA. Development of a Live Topical Microbicide for Wo source ↗
Aug 31, 2007 NIH award 5U01AI066708-03 FY2007: $574,751 awarded for that fiscal year; activity U01 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., Mountain View, CA. MucoCept: a Live Topical Microbicide for Women source ↗
Jun 25, 2007 NIH award 5U19AI060615-04 FY2007: $1,330,931 awarded for that fiscal year; activity U19 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., Mountain View, CA. Lactobacilli as a Delivery Vehicle for Microbici source ↗
2007 NIH award 5U19AI060615-04 FY2007: $237,460 awarded for that fiscal year; activity U19 (OTHER_NIH); PI MARTIN, PATRICK; recipient as written: OSEL, INC., Mountain View, CA. Core--Microbiology source ↗
2007 NIH award 5U19AI060615-04 FY2007: $253,485 awarded for that fiscal year; activity U19 (OTHER_NIH); PI LEWICKI, JOHN A; recipient as written: OSEL, INC., Mountain View, CA. Lactobacilli Expressing Multivalent CD4 as a source ↗
2007 NIH award 5U19AI060615-04 FY2007: $264,049 awarded for that fiscal year; activity U19 (OTHER_NIH); PI LUSSO, PAULO; recipient as written: OSEL, INC., Mountain View, CA. RANTES Peptides source ↗
2007 NIH award 5U19AI060615-04 FY2007: $575,937 awarded for that fiscal year; activity U19 (OTHER_NIH); PI MARKHAM, RICHARD B.; recipient as written: OSEL, INC., Mountain View, CA. Anti-ICAM-i scFv from lactobacilli as a source ↗
Jun 20, 2006 NIH award 5U19AI060615-03 FY2006: $1,463,248 awarded for that fiscal year; activity U19 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., Mountain View, CA. Lactobacilli as a Delivery Vehicle for Microbici source ↗
May 31, 2006 NIH award 5U01AI066708-02 FY2006: $583,184 awarded for that fiscal year; activity U01 (OTHER_NIH); PI XU, QIANG; recipient as written: OSEL, INC., Mountain View, CA. MucoCept: a Live Topical Microbicide for Women source ↗
2006 NIH award 5U19AI060615-03 FY2006: $267,351 awarded for that fiscal year; activity U19 (OTHER_NIH); PI MARTIN, PATRICK; recipient as written: OSEL, INC., Mountain View, CA. Microbiology Core source ↗
2006 NIH award 5U19AI060615-03 FY2006: $297,287 awarded for that fiscal year; activity U19 (OTHER_NIH); PI LUSSO, PAULO; recipient as written: OSEL, INC., Mountain View, CA. RANTES Peptides source ↗
2006 NIH award 5U19AI060615-03 FY2006: $648,424 awarded for that fiscal year; activity U19 (OTHER_NIH); PI MARKHAM, RICHARD B.; recipient as written: OSEL, INC., Mountain View, CA. Anti-ICAM-i scFv from lactobacilli as a source ↗
2006 NIH award 5U19AI060615-03 FY2006: $285,394 awarded for that fiscal year; activity U19 (OTHER_NIH); PI LEWICKI, JOHN A; recipient as written: OSEL, INC., Mountain View, CA. Lactobacilli Expressing Multivalent CD4 as a source ↗
Sep 21, 2005 NIH award 1R43DK070392-01 FY2005: $121,667 awarded for that fiscal year; activity R43 (SBIR); PI PARKS, THOMAS P; recipient as written: OSEL, INC., Mountain View, CA. Oral Immunotherapy for C. difficile Disease via B source ↗